Akt Activation Protects Hippocampal Neurons from Apoptosis by Inhibiting Transcriptional Activity of p53*

Atsushi YamaguchiDagger §, Michio TamataniDagger §, Hideo MatsuzakiDagger §, Kazuhiko Namikawa||, Hiroshi Kiyama§||, Michael P. Vitek**, Noriaki MitsudaDagger §, and Masaya TohyamaDagger §

From the Dagger  Department of Anatomy and Neuroscience, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan, the || Department of Anatomy, Asahikawa Medical College, 4-5-3-11 Nishikagura, Asahikawa, Hokkaido 078-8510, Japan, the ** Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, and § Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan

Received for publication, September 19, 2000, and in revised form, October 25, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Survival factors suppress apoptosis by activating the serine/threonine kinase Akt. To investigate the molecular mechanism underlying activated Akt's ability to protect neurons from hypoxia or nitric oxide (NO) toxicity, we focused on the apoptosis-related functions of p53 and caspases. We eliminated p53 by employing p53-deficient neurons and increased p53 by infection with recombinant adenovirus capable of transducing p53 expression, and we now show that p53 is implicated in the apoptosis induced by hypoxia or NO treatments of primary cultured hippocampal neurons. Although hypoxia and NO induced p53, treatment with insulin-like growth factor-1 significantly inhibited caspase-3-like activation, neuronal death and transcriptional activity of p53. These insulin-like growth factor-1 effects are prevented by wortmannin, a phosphatidylinositol 3-kinase inhibitor. Adenovirus-mediated expression of activated-Akt kinase suppressed p53-dependent transcriptional activation of responsive genes such as Bax, suppressed caspase-3-like protease activity and suppressed neuronal cell death with no effect on the cellular accumulation and nuclear translocation of p53. In contrast, overexpression of kinase-defective Akt failed to suppress these same activities. These results suggest a mechanism where Akt kinase activation reduces p53's transcriptional activity that ultimately rescues neurons from hypoxia- or NO-mediated cell death.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The p53 tumor suppressor gene has recently been shown to play an important role in regulating apoptosis for neurons and a number of other cell types (1). Hypoxic insult, as well as excitotoxic stimulation, involves excessive production of nitric oxide (NO) and has have been shown to increase p53 production with concomitant increases in neuronal apoptosis (2). In general, p53-mediated apoptosis requires a p53 protein that functions to modulate transcription of certain genes. Important examples of such activated genes include the apoptosis-inducing Bax gene (3) and the KILLER/DR5 gene (4).

Following exposure to toxic treatments, a number of peptide factors including neurotrophins and growth factors such as insulin-like growth factor 1 (IGF-1)1 have been found to enhance neuronal survival (5). In recent years, considerable advances have been made in understanding the signal transduction pathway activated by these growth factors. Among them, the serine/threonine kinase termed Akt appears to play a central role in the survival of a number of cell types (6-9). Recently, four Akt substrates were identified that are also components of the cell's intrinsic death machinery: the pro-apoptotic Bcl-2 family member known as Bad (10, 11), the caspase-9 protease (12), Ikappa B kinase alpha  (IKKalpha ) (13), and a member of the Forkhead family of transcription factors known as FKHRL1 (14-16). In each case, phosphorylation by Akt kinase inhibits these protein's pro-apoptotic function, thereby accounting for at least part of the survival effect imparted by activated Akt kinase.

We now report that activated Akt significantly impairs p53-dependent neuronal apoptosis and impairs induction of Bax in response to treatment with hypoxia, NO, or adenovirus-mediated expression of p53. We further show that activated Akt strongly inhibits p53-dependent transactivation of target genes with no apparent effect on p53-protein accumulation, subcellular localization, and phosphorylation status of p53. These findings suggest a mechanism where activated Akt kinase inhibits p53-mediated transactivation to apparently block subsequent apoptosis of the neuron.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

p53-deficient Mice-- Homozygous p53-deficient mice were obtained from the Oriental Yeast Co., Ltd. (Tokyo, Japan). Originally on a mixed C57BL6/CBA strain, p53-deficient mice were backcrossed to C57BL6 (five times) so that the majority of their genetic background is C57BL6. Fifth generation heterozygous p53 knockout mice on the C57BL6 background were mated to one another to produce the homozygous p53 knockout mice used in this study. The genotypes of all mice were confirmed by PCR using DNA extracted from the tails according to the protocol described previously (17). The primers were mixtures of 1) a genomic sequence in intron 1 and upstream of exon 2 in the p53 gene (5'-AATTGACAAGTTATGCATCCAACAGTACA-3'), 2) a genomic sequence in exon 4 of the p53 gene (5'-ACTCCTCAACATCCTGGGGCAGCAACAGAT-3'), and 3) a sequence from the neomycin resistance gene (5'-GAACCTGCGTGCGTGCAATCCATCCATCTTGTTCAATG-3'). A 500-base pair PCR product represents the wild-type p53 gene and a 800-base pair PCR product represents the disrupted p53 gene.

Cell Culture-- Hippocampal neurons were prepared from postnatal day -1 p53 wild-type and deficient mice and from embryonic day 18 Harlan Sprague Dawley rat embryos, as described previously (18, 19). Briefly, fetal hippocampi were dissected and digested with 0.25% trypsin for 20 min at room temperature in calcium/magnesium-free Hanks' balanced salt solution (Life Technologies, Inc.). Tissues were further dissociated by repeated trituration. The cells were seeded at a density of 1 × 106 cells/cm2 on plates coated with poly-L-lysine (10 µg/ml) (Falcon Lab and Maintainware, Lincoln Park, NJ) and grown in Dulbecco's modified Eagle's medium supplemented with 10% inactivated fetal calf serum, 30 mM glucose, and 0.5% (v/v) penicillin-streptomycin at 37 °C in a humidified atmosphere of 5% CO2 and 95% room air. To inhibit growth of glial cells, cytosine arabinoside (10 µM) was added to the cultures 48 h after seeding. All experiments were performed in 8-10-day-old cultures (8-10 DIV).

Experimental Treatments-- The growth medium was replaced with a serum-free medium that consisted of Dulbecco's modified Eagle's medium supplemented with 30 mM glucose and 0.5% (v/v) penicillin-streptomycin. At 24 h after the replacement, cells were treated for 6 h with IGF-1 or vehicle (saline) and exposed to hypoxia or a NO donor, sodium nitroprusside (SNP; Sigma). Human recombinant IGF-1 was purchased from Sigma. Hypoxia treatment was performed using an incubator attached to a hypoxia chamber (Coy Laboratory Products, Ann Arbor, MI) that maintained a humidified atmosphere with low oxygen tension (pO2; 12-14 Torr) as described previously (20). In PI 3-kinase inhibition studies, the PI 3-kinase inhibitor wortmannin (Sigma) was added to the cultures 15 min before treatment with IGF-1.

Recombinant Adenovirus-- The generation of recombinant adenovirus containing constitutively active Akt (AxCALNmyrAkt) or kinase-deficient Akt gene (AxCAKDAK179M) has been described previously (21). In brief, AxCALNmyrAkt encodes constitutively active Akt (myr-Akt) that lacks a pleckstrin homology domain but contains a Src myristoylation signal sequence fused to its amino-terminal end. The myr-Akt gene is subcloned into the Cre-inducible expression cassette, pAxCALNLw, which is normally not expressed because of the placement of the neomycin resistance gene. Efficient production of a nuclear location signal-tagged Cre recombinase under control of the CAG promoter (22) permits Cre-mediated excision of the neomycin resistance gene from the pAxCALNLw vector allowing expression of the heterologous target gene. The kinase-defective Akt (tagged with hemagglutinin to its NH2 terminus) was prepared by PCR where Akt1 K179M in pBT-701 (kindly provided by Dr. Kikkawa, Kobe University, Kobe, Japan), was used as a template. DNA fragments generated by PCR were confirmed by DNA sequence analysis. Then, the kinase-defective Akt gene tagged with hemagglutinin was cloned into the pAxCAwt expression vector and was designated as pAxCAAktK179M.

The recombinant adenovirus vectors AxCANCre, which expresses Cre recombinase; AxCALNLZ, which expresses LacZ when a sufficient amount of Cre recombinase is expressed; and AxCANLZ, which expresses LacZ under control of the CAG promoter, were generously provided by Dr. Saito (University of Tokyo, Tokyo, Japan). Another recombinant adenovirus vector Ad5CMVp53, which expresses p53 protein under the control of CMV promoter, was generously provided by Dr. Roth (University of Texas, Houston, TX) (23). All viruses were grown in 293 cells and purified by CsCl2 gradient centrifugation. Virus titers were determined by plaque assay and concentrated virus stored at -80 °C.

Infection was carried out by adding recombinant adenovirus to serum-containing medium. The cells were incubated with virus-containing media at the indicated multiplicity of infection at 37  °C for 60 min with constant agitation. The medium was changed, and the cells were incubated at 37 °C for 24 h before exposure to hypoxia or a NO donor, SNP, or were untreated as stated.

Assessment of Cell Viability-- Neuronal cell viability was assessed by determining the release of lactate dehydrogenase into the culture medium thereby indicating a loss of membrane integrity and cell death. Lactate dehydrogenase activity was measured using a commercial kit (Kyokuto Chemical Co., Tokyo, Japan) in which a colorimetric assay measures the pyruvate-mediated conversion of 2,4-dinitrophenylhydrazine into a visible hydrazone precipitate. Percent neuronal viability was expressed as (1 - experimental value/maximum release) × 100, where the maximum release was obtained after exposure of untreated control cultures to 0.2% Triton X-100 for 15 min at 37 °C.

Levels of cytoplasmic, histone-associated DNA fragments were assayed using the Cell Death enzyme-linked immunosorbent assay (Roche Molecular Biochemicals, Mannheim, Germany) according to manufacture's protocol. In brief, the cytosolic fraction (13,000 × g supernatant) of ~500 cultured cells was used as an antigen source in a enzyme-linked immunosorbent sandwich assay with primary anti-histone antibody coated to the microtiter plate and secondary anti-DNA antibody coupled to peroxidase. From the absorbance values, the -fold increase of DNA fragmentation was calculated as (absorbance of treated cells - absorbance of blank)/(absorbance of control cells - absorbance of blank) where nontreated cells were used as controls.

Caspase-3-like Enzyme Activity-- Caspase-3-like activity was measured by spectrophotometric assay as described previously (24). Briefly, neurons were suspended in buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, and 10 mM EGTA), and then incubated with 10 µM digitonin (Sigma) at 37 °C for 10 min, followed by centrifugation at 15,000 rpm for 3 min. Protein concentration in the resulting supernatant was measured using a DC protein assay kit (Bio-Rad). Then, the supernatant containing 30 µg of protein was incubated with 50 µM enzyme substrate, 7-amino-4-methylcoumarin (AMC)-DEVD, at 37 °C for 1 h. Levels of released AMC were measured using an excitation wavelength of 380 nm and an emission wavelength of 460 nm with a spectrofluorometer (Hitachi F-3000, Hitachi, Tokyo, Japan). One unit was defined as the amount of enzyme required to release 0.22 nmol of AMC/min at 37 °C. Caspase-3-like activity of control neurons was 47.1 ± 2.7 units/mg of protein.

Western Blot Analysis-- Cell extracts for Western blot analysis were prepared by washing the cells three times with PBS and lysing them in sample buffer (50 mM Tris-HCl, pH 8.0, 20 mM EDTA, 1% SDS, and 100 mM NaCl). The samples were boiled for 5 min before subjecting 20-µg aliquots to electrophoresis on 12.5% SDS-PAGE gels. After the proteins were transferred onto polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA), the membrane was incubated in blocking buffer (1× PBS, 5% nonfat dried milk) for 1 h at room temperature and then probed with a primary antibody in blocking buffer overnight at 4 °C. The membrane was washed four times in PBS containing 0.3% Tween 20, probed with the secondary antibody in blocking buffer for 1 h at room temperature, and washed again in PBS containing 0.05% Tween 20. Detection of signal was performed with an enhanced chemiluminescence detection kit (Amersham International, Little Chalfont, United Kingdom). The primary antibodies used were anti-p53 monoclonal antibody (DO-1; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-Bax polyclonal antibody (P-19: Santa Cruz Biotechnology, Inc.), anti-mouse Akt polyclonal antibody (New England Biolabs), anti-mouse phospho-Akt polyclonal antibody that recognizes Akt only when phosphorylated at Ser-473 (9270, New England Biolabs), and anti-mouse beta -actin monoclonal antibody (Sigma).

RNA Isolation and RT-PCR-- Total RNA derived from 2 × 107 cells was extracted from primary cultures of rat neurons by the acid guanidium-thiocyanate/phenol chloroform method. For RT-PCR, 5 µg of total RNA was reversed-transcribed using oligo(dT) and reverse transcriptase from Moloney murine leukemia virus (Life Technologies, Inc.) in a volume of 25 µl. For PCR amplification, specific oligonucleotide primer pairs (10 pmol each) were incubated with 1 µl of cDNA template in a 20-µl PCR reaction mixture containing 1.5 mM MgCl2, 25 mM KCl, 10 mM Tris, pH 9.2, 1 µl of deoxynucleotides (1 mM each), and 1 unit of Taq polymerase. The sequences of primers used in this study were as follows: Bax sense primer (5'-TGGTTGCCCTTTTCTACTTTG-3') and Bax antisense primer (5'-GAAGTAGGAAAGGAGGCCATC-3') and as an internal control, beta -actin sense primer (5'-TGCCCATCTATGAGGGTTACG-3') and beta -actin antisense primer (5'-TAGAAGCATTTGCGGTGCACG-3'). Dilutions of cDNA were amplified for 23-26 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s. The amplified PCR products at each cycle number were analyzed by 1% agarose gel electrophoresis and ethidium bromide staining. The product of constitutively expressed beta -actin mRNA served as the internal standard. The amplified PCR products were analyzed by 1% agarose gel electrophoresis and ethidium bromide staining. The product of constitutively expressed beta -actin mRNA served as the control. All the products were assayed in the linear response range of the RT-PCR amplification process; the cycle number used was determined by finding the midpoint of linear amplification on a sigmoid curve for both amplification products with cycle numbers of 24-30 plotted against band density (25). The identity of each PCR product was confirmed by subcloning the amplified cDNAs into the pGEM-T vector (Promega) and sequencing.

Electrophoretic Mobility Shift Assay (EMSA)-- Nuclear extracts were prepared from primary neuronal cultures according to published method (26) with some modifications. In brief, cells were plated at a density of 2 × 106 cells/60-mm dish and were harvested by scraping and washing in 0.5 ml of cold PBS. The cells were then washed once in 0.1 ml of cold buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and 0.5 mM dithiothreitol). The washed pellets were then suspended in 50 µl of buffer A plus 0.1% Nonidet P-40 supplemented with 1 µg/ml leupeptin and aprotinin and were incubated on ice for 10 min. After incubation, the pellets were mixed briefly by vortexing and were centrifuged at 10,000 rpm at 4 °C for 5 min in a microcentrifuge. The supernatant was carefully removed, and the nuclear pellet was resuspended in 20 µl of cold buffer C (20 mM HEPES, pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.15 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride) containing 1 µg/ml leupeptin and aprotinin and incubated on ice for another 15 min with intermittent vortexing. The extracts were then centrifuged at 10,000 rpm at 4 °C for 10 min, and the supernatant was divided into aliquots and frozen at -70 °C. Protein concentrations were determined using Bio-Rad protein assay kit.

To assay binding activity, a double-strand oligonucleotide containing the sequence corresponding to the p53 consensus site (5'-AGCTTAGACATGCCTAGACATGCCTA-3') (27) was end-labeled with [gamma -32P]ATP using T4 kinase (Life Technologies, Inc.). Unincorporated nucleotides were removed using Sephadex G-50 column (Amersham Pharmacia Biotech). Binding reactions were carried out in a final volume of 25 µl consisting of 10 mM HEPES, pH 7.9, 4 mM Tris-HCl, 60 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, 10% glycerol, 1.5 mg/ml bovine serum albumin, 2 µg of poly(dI-dC), 2-10 µg of nuclear extract, and 0.5 ng of 32P-labeled oligonucleotide probe (50,000 cpm). Reactions were incubated for 20 min at room temperature. Binding reactions were subjected to nondenaturing polyacrylamide electrophoresis through 4% gels in a 1× Tris borate-EDTA buffer system. Gels were dried and subjected to autoradiography.

Luciferase Assay-- Primary cultured rat neurons were plated in six-well tissue culture dishes at 9 × 104 cells/well and used for transient transfection at DIV 7. Cells were then cotransfected with 0.3 pmol of a p53-Luc plasmid that contains a firefly luciferase reporter gene driven by a basic promoter element and a TATA box, which are joined to a tandem repeat of a p53 binding element (Stratagene), together with 0.3 pmol of pRL-TK plasmid, which contains an herpes simplex virus thymidine kinase promoter upstream of the Renilla luciferase gene (Promega). As controls, pGL3 basic vector or pGL3 promoter plasmids that contain an SV40 promoter upstream of the firefly luciferase gene (Promega) are cotransfected with pRL-TK plasmid. Transfections are carried out using the modified calcium phosphate method as described previously (28).

Transfected cells were cultured for 24 h, washed twice with 2 ml of Ca2+- and Mg2+-free PBS and lysed with Passive Lysis Buffer (Promega). Firefly luciferase and Renilla (sea pansy) luciferase activities were measured sequentially using a dual-luciferase reporter assay system (Promega) and a Lumat LB9501 luminometer (EG&G, Berthold). After measuring the firefly luciferase signal (LAF) and the Renilla luciferase signal (LAR), the relative luciferase activity (RLA) was calculated as: RLA = LAF/LAR, where relative RLA was calculated as a percentage, i.e. %RLA = RLA/(RLA)max.

In Vivo Kinase Assay-- To examine the effect of Akt activation on the phosphorylation status of p53, in vivo kinase assays were performed according to the published method (29). Neurons derived from rat fetal brains were seeded in 35-mm dishes at the density of 1-2 × 106 cells/dish. Cells were incubated in a phosphate-free medium for 30 min and then labeled with 32P for 3 h in a medium containing 0.2 mCi/ml [32P]orthophosphate. After 32P labeling, they were lysed in RIPA buffer (0.02 M Tris-HCl, pH 7.4, 0.15 M NaCl, 2 mM EDTA, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS) containing protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin) and phosphatase inhibitors (50 mM NaF, 1 mM Na3VO4). p53 proteins were recovered by immunoprecipitation with anti-p53 antibody and subjected to SDS-PAGE, which was dried prior to analysis by autoradiography.

Statistical Analysis-- Results are presented as mean ± S.E. Experimental groups were compared by analysis of variance, followed by Scheffe's post hoc test. p values less than 0.05 were considered significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

p53 Is Involved in Caspase-3-like Activity and Neuronal Death Mediated by Hypoxic and Nitric Oxide Treatments-- To address the possibility that accumulation of p53 plays a role in cell death following treatment with hypoxia or a NO donor, SNP, we compared viabilities of primary hippocampal neurons derived from wild-type or p53-null mice. Treatment with hypoxia or SNP (50 µM) induced significantly greater degrees of neuronal loss, DNA fragmentation, and caspase-3-like activation in neurons derived from wild-type mice as compared with those from p53-null mice (Fig. 1A, a-c). Administration of the Ac-DEVD-CHO, a peptide inhibitor of caspase-3-like protease (1 µM), which completely inhibited casapse-3-like activation (Fig. 1A, c), reduced the proportion of hypoxia-induced or SNP-induced cell death (Fig. 1A, b) and DNA fragmentation (Fig. 1A, a), suggesting that increased protease activity is required for cell death. Furthermore, treatment with hypoxia or SNP significantly increased the levels of p53 protein (Fig. 1A, d). These results demonstrated that apoptosis following hypoxia or SNP treatments is prominently associated with increased p53 expression.



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   p53 is involved in hypoxia- and NO-mediated neuronal death. A, primary cultured p53-null (p53(-/-)) or wild-type (p53(+/+)) mouse hippocampal neurons were exposed to hypoxia or SNP (50 µM) for 24 h, and then levels of cytoplasmic histone-associated DNA fragments (a), neuronal viability (b), and caspase-3-like activity (c) were assayed as described in text. Extracts from cells were subjected to 10% SDS-PAGE, and blots were probed with antibody to p53 (d). DEVD, Ac-DEVD-CHO (1 µM). Data are mean ± S.E. of four independent experiments performed in triplicates. *, p < 0.05 versus wild-type. B, primary cultured p53-deficient (p53(-/-)) mouse hippocampal neurons were infected or not infected with Ad5CMVp53 (Adp53) or AxCALNLZ (AdLZ) at the indicated m.o.i. At 24 h after viral infection, extracts from cells were subjected to 10% SDS-PAGE and blots were probed with antibody to p53 (a). After 24 h of infection, levels of DNA fragmentation (b), neuronal viability (c), and caspase-3-like activity (d) were measured. Data are mean ± S.E. of four independent experiments performed in triplicates. *, p < 0.05 versus control, uninfected cells; **, p < 0.05 versus Adp53 (50 m.o.i.).

To further demonstrate that p53 is involved in neuronal apoptosis, we used a strategy of adenovirus infection to transduce the expression of p53 protein in cultures of hippocampal neurons from p53-null mice. Western blot analysis revealed that cultured neurons deficient in p53 gene and infected with Ad5CMVp53, which expresses human wild-type p53 protein under control of the CMV promoter, displayed increased levels of p53 protein at 24 h after infection that was dependent on the multiplicity of infection (m.o.i.) as compared with uninfected cells or with cells infected with a control virus, AxCANLZ (Fig. 1B, a). Infection with Ad5CMVp53 (50 and 100 m.o.i.) also increased neuronal death, DNA fragmentation, and caspase-3-like activity at 24 h after infection. (Fig. 1B, b-d). Moreover, pretreatment of neurons with the caspase-protease inhibitor, Ac-DEVD-CHO (1 µM), significantly inhibited neuronal death induced by infection with Ad5CMVp53 (Fig. 1B, c). DNA fragmentation, neuronal viability, and caspase-3-like proteolytic activity of AxCANLZ-infected cells were similar to those of control, uninfected neurons (data not shown). These results are consistent with the hypothesis where increased levels of p53 expression are proportionally associated with increased apoptotic cell death.

IGF-1-mediated Signaling Pathways Inhibit p53-induced Neuronal Death-- Growth factors such as IGF-1 appear to play a neuroprotective role against ischemic or excitotoxic insult (30). To assess the role of IGF-1 in the prevention of p53-mediated neuronal death, we examined the effect of IGF-1 on wild-type or p53-null neurons exposed to hypoxia or SNP treatment. Pretreatment with IGF-1 conferred ~70% protection from hypoxia- or SNP-induced cell death, 60% reduction in DNA fragmentation, and 70% inhibition of caspase-3-like activation in wild-type neurons with these effects being blocked by treatment with wortmannin (20 nM), an inhibitor of PI 3-kinase (Fig. 2, A-C). On the other hand, IGF-1 treatment in p53-null neurons did not significantly change the measured parameters of apoptosis observed in non-IGF-1-treated p53-null neurons (Fig. 2, A-C). These results clearly suggest that IGF-1 protects neurons from p53-mediated toxicity through PI 3-kinase activation.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   IGF-1 inhibits p53-induced neuronal death through PI 3-kinase. Neurons derived from wild-type (p53(+/+)) or p53-null mice (p53(-/-)) pretreated with IGF-1 (100 ng/ml) or vehicle (saline) in the presence or absence of wortmannin (W) (20 nM) were exposed to hypoxia or SNP (50 µM) for 24 h, and then neuronal viability (A), DNA fragmentation (B), and caspase-3-like activity (C) were measured as described in text. Data are mean ± S.E. of four independent experiments performed in triplicates. *, p < 0.05 versus non-IGF-1-treated p53(+/+) neurons; #, p < 0.05 versus IGF-1-treated p53(+/+) neurons in the absence of wortmannin.

IGF-1 Mediates Inhibited DNA Binding and Transcriptional Activity of p53 with No Effect on p53 Protein Accumulation-- The functional status of p53 to activate transcription strongly correlates with its ability to bind specific DNA sequences on target genes (31). To examine the effect of IGF-1 on p53 accumulation, DNA binding activity, and transcriptional activity, primary rat hippocampal neurons were pretreated with or without IGF-1 in the presence or absence of wortmannin followed by exposure to hypoxia or SNP treatments for up to 24 h. 24 h after exposure to hypoxia or SNP, cells were lysed and the extracts were subjected to Western blot analysis using anti-p53 monoclonal antibody. As shown in Fig. 3A, IGF-1 treatment with or without pretreatment of wortmannin had no effect on p53 accumulation in neurons exposed to hypoxia or SNP treatment. We then examined the effect of IGF-1 on p53's DNA binding activity by EMSAs. Nuclear extract were prepared 8 h after treatment with hypoxia or SNP, and the EMSAs were performed using the p53 consensus response element as a probe (5'-AGCTTAGACATGCCTAGACATGCCTA-3'). As shown in Fig. 3B, treatment with IGF-1 inhibits hypoxia- or SNP-induced increases in p53's DNA binding activity. Pretreatment with wortmannin apparently antagonized the IGF-1 effect and allowed increased p53 DNA binding activity. Excess unlabeled probe effectively competed the binding of the labeled probe (Fig. 3B). To examine whether IGF-1 affects the transactivation potential of p53, we performed reporter gene assays using reporter plasmids containing a tandem repeat of a p53 consensus response element placed upstream of a luciferase cDNA (p53-Luc, Stratagene). 24 h after transient transfection with the reporter plasmid, cells were exposed to hypoxia or SNP treatment for 8 h in the presence or absence of IGF-1. Although we observed 8-9-fold induction of the luciferase activity by hypoxia or SNP treatment, pretreatment with IGF-1 remarkably reduced the increase in the transcriptional activation of p53, which was prevented by wortmannin (Fig. 3C).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of IGF-1 on cellular accumulation, DNA binding, and transcriptional activity of p53. Cultured rat hippocampal neurons pretreated with IGF-1 (100 ng/ml) or saline (vehicle) in the presence or absence of wortmannin (W; 20 nM) were exposed to hypoxia or SNP (50 µM). A, Western blot analysis. Extracts of neurons were subjected to 10% SDS-PAGE. Then the blots were probed with antibody to p53. Visualization of proteins was performed with ECL. B, EMSAs. Nuclear extracts prepared from neurons exposed to hypoxia or SNP for 8 h were assayed by EMSAs. "Cold" means the addition of excess of unlabeled oligonucleotide containing p53 consensus binding element into binding reactions as indicated -fold. The arrowhead points to the p53/p53 consensus binding element oligonucleotide complex. C, reporter gene assays. Primary hippocampal neurons were transiently cotransfected with reporter construct either p53-Luc plasmid or control plasmid, together with pRL-TK plasmid, and then neurons were treated with IGF-1 in the presence or absence of wortmannin. After 24 h of treatments, cultures were exposed for 8 h to hypoxia or SNP (50 µM) and luciferase activity was assayed. Relative luciferase activity was expressed as -fold increase, compared with control LacZ-expressing neurons without any stimuli (Control). Data are mean ± S.E. of four independent experiments performed in triplicate. *, p < 0.05 versus nontreated neurons.

Activation of Akt Kinase Inhibits p53-mediated Neuronal Death-- Akt, a downstream target of PI 3-kinase, has been implicated in transducing growth factor survival signals in various cell types including neurons (32). As we found that IGF-1 inhibits p53-mediated neuronal death through activation of PI 3-kinase, we then assessed a potential function of Akt activation in the prevention of p53-mediated neuronal death using an adenoviral vector capable of expressing constitutively active Akt with the Src myristoylation signal fused in-frame to the c-Akt coding sequence (AxCALNLmyrAkt). As a control, we employed another vector capable of expressing a kinase-defective Akt mutant (AxCAAktK179M) in which the lysine of the adenosine triphosphate-binding site at position 179 was replaced by a methionine. Primary hippocampal neurons were infected with AxCANCre and either AxCALNmyrAkt or AxCALNLZ, a control virus carrying LacZ instead of myrAkt. Other cells were infected with AxCAAktK179M, and whole cell extracts were prepared for Western blot analysis 24 h after viral infection. Western blot analysis revealed increased levels of Akt and phosphorylated Akt in neurons infected simultaneously with AxCANCre (2 m.o.i.) and AxCALNmyrAkt (2 and 10 m.o.i.), in a m.o.i.-dependent manner (Fig. 4A). As the myrAkt lacks its pleckstrin homology domain, the size of the protein product (47.5 kDa) is smaller than endogenous Akt or the product of kinase-defective Akt (62 kDa). The cells infected with AxCANCre (2 m.o.i.) and AxCALNLZ (10 m.o.i.) did not show increased levels of Akt protein or phosphorylated Akt protein (Fig. 4A). Infection with AxCANCre (2 m.o.i.) and Ax CALNLmyrAkt (10 m.o.i.) to express activated Akt significantly reduced neuronal death and caspase-3-like activation induced by hypoxia, SNP, and p53 adenovirus infection compared with infection with AxKDAkt (10 m.o.i.) to express inactive, kinase-defective Akt protein (Fig. 4, B and C). Similarly, infection with AxCALnLZ (10 m.o.i.) failed to reduce neuronal death compared with cells expressing activated-Akt kinase.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Activation of Akt kinase inhibits p53-induced neuronal death. A, assessment of adenovirus-mediated expression of active and kinase-defective forms of Akt. Cultured rat hippocampal neurons were infected with AxCANCre (AxCre) and AxCALNLZ (AxLacZ) or AxCALNLmyrAkt (AxAkt), or AxCAAktK179M (AxKDAkt) at the indicated m.o.i. 24 h after infection, cell extracts were subjected to 10% SDS-PAGE and blots were probed with antibodies for Akt or phospho-Akt. B and C, cultures were infected with both AxCANCre (AxCre; 2 m.o.i.) and AxCALNLZ (AxLacZ; 10 m.o.i.) or AxCALNLmyrAkt (AxAkt; 10 m.o.i.), or AxCAAktK179M (AxKDAkt; 10 m.o.i.) alone. 24 h after infection, neurons were exposed for 24 h to hypoxia, 50 µM SNP or infected with Adp53 (50 m.o.i.). Then, the neuronal viability (B) and caspase-3-like activity (C) were assessed as described in the text. Data are mean ± S.E. of four independent experiments performed in triplicate. *, p < 0.05 versus neurons infected with both AxCre and AxLacZ in each treatment.

Effect of Akt Kinase Activation on p53 Accumulation, Nuclear Translocation, Phosphorylation Status, DNA Binding Activity, and Transcriptional Activation-- Since we show that IGF-1 reduces the DNA binding activity and transcriptional activity of p53 without changing p53 protein accumulation through PI 3-kinase (Fig. 3, A-C), we further tested whether Akt activation inhibits changes in p53 accumulation, nuclear translocation, DNA binding activity, and transcriptional activity that are induced by hypoxia treatment, SNP treatment, or Adp53 infection. Cells infected with both AxCANCre (2 m.o.i.) and AxCALNLmyrAkt (10 m.o.i.) or AxCALNLZ (10 m.o.i.) or infected with AxCAAktK179M (10 m.o.i.) were exposed to hypoxia or SNP (50 µM) or infected with Ad5CMVp53 (50 m.o.i.). Cellular accumulation, nuclear translocation, and DNA binding activity of p53 were assessed at 24, 12, and 8 h, respectively, after exposure to hypoxia or SNP, and at 24 h after AdCMVp53 infection. Cellular accumulation and nuclear translocation of p53 were observed following all the treatments and were not changed by expression of active Akt, kinase-defective Akt, or LacZ (Fig. 5, A and B). However, EMSAs using the p53 consensus response element as a probe showed that expression of active Akt, but not of kinase-defective Akt or LacZ, did inhibit the hypoxia-, NO-, or Adp53-induced increase in DNA binding activity of functional p53 to the consensus binding oligonucleotide (Fig. 5C). Consistent with this finding, reporter gene assays using reporter plasmids containing tandem repeats of p53 consensus response element placed upstream of a luciferase cDNA revealed that expression of activated Akt, but not of kinase-defective Akt or LacZ, significantly reduced the induction of the luciferase promoter that is controlled by the p53-responsive promoter following hypoxia, SNP, or Adp53 infection (Fig. 5D). Next, to examine the possibility that Akt directly or indirectly phosphorylates p53 and thereby regulates p53's transcriptional activity, the phosphorylation status of p53 was assessed by an in vivo kinase assay. Rat primary cultured neurons were infected with both AxCANCre (2 m.o.i.) and AxCALNLmyrAkt (10 m.o.i.) or AxCALNLZ (10 m.o.i.) or infected with AxKDAkt (10 m.o.i.) alone. After 24 h of incubation, cells were infected with Ad5CMVp53 (50 m.o.i.) and incubated for an additional 24 h to overexpress p53. Then cells were incubated for 3 h in the medium containing 0.2 mCi/ml [32P]orthophosphate. The phosphorylation status of p53 was monitored by immunoprecipitating p53 protein and quantifying p53-associated radioactivity by autoradiography. p53 protein expression was monitored by Western blotting analysis. As shown in Fig. 5E, our in vivo kinase assay showed that neither expression of active or kinase-defective Akt has any effect on phosphorylation status of p53 (Fig. 5E).



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of Akt activation on cellular accumulation, nuclear translocation, DNA binding activity, transcriptional activation, and phosphorylation status of p53. A-C, cultured rat hippocampal neurons were infected AxCANCre (AxCre; 2 m.o.i.) and AxCALNLZ (AxLacZ; 10 m.o.i.) (Cont. and lane 1) or AxCALNLmyrAkt (AxAkt; 10 m.o.i.) (lane 2) or AxCAktK179M (AxKDAkt; 10 m.o.i.) (lane 3). At 24 h of infection, neurons were exposed to hypoxia (a) or SNP (50 µM) (b), or infected with Ad5CMVp53 (Adp53) (50 m.o.i.) (c). After treatment with hypoxia, SNP or Ad5CMVp53, p53 protein amount in cell lysate (A) and subcellular fractions (n, nuclear; c, cytosolic) (B) was assessed by Western blot. Immunoreactive beta -tubulin and cytosolic beta -actin were used to confirm the identity of the subcellular fractions and protein loading amount, respectively. C, EMSAs. After 8 h of treatment with hypoxia or SNP, or 24 h of infection with Ad5CMVp53, nuclear extracts prepared from neurons were assayed in EMSAs using p53 consensus response element as the 32P-labeled oligonucleotide. The arrowhead points to the p53/p53 consensus binding element oligonucleotide complex. Cont, control LacZ-expressing cells without treatment with hypoxia, SNP, or Ad5CMVp53. D, reporter gene assays. Primary hippocampal neurons were transiently cotransfected with reporter construct either p53-Luc plasmid or control plasmid, together with pRL-TK plasmid, and then neurons were infected or not infected with AxCANCre (2 m.o.i.) and AxCALNLZ (10 m.o.i.) or AxCALNLmyrAkt (10 m.o.i.), or AxCAAktK179M (10 m.o.i.) alone. After 24 h of virus infection, cultures were exposed for 8 h to hypoxia or SNP, or for 24 h infected with Ad5CMVp53 (50 m.o.i.) and luciferase activity was assayed. Relative luciferase activity was expressed as -fold increase, compared with control LacZ-expressing neurons without any stimuli (Cont). Data are mean ± S.E. of four independent experiments performed in triplicates. *, p < 0.05 versus control LacZ-expressing cells in each treatment. E, phosphorylation status of p53. Cultured rat hippocampus neurons were infected with both AxCANCre (2 m.o.i.) and AxCALNLZ (10 m.o.i.) or AxCALNLmyrAkt (10 m.o.i.), or infected with AxCAAktK179M (10 m.o.i.) alone. At 24 h of viral infection, neurons were infected with Ad5CMVp53 (50 m.o.i.) (lanes 2-5) and incubated for additional 24 h. Neurons were then metabolically labeled in a medium containing 0.2 mCi of [32P]orthophosphate/ml. After 32P labeling, p53 proteins were recovered by anti-p53 antibody immunoprecipitation and subjected to SDS-PAGE, which was dried for analysis by autoradiography. The loading internal control was assessed by Western blot analysis for p53.

Akt Activation Inhibits p53-mediated Expression of Bax, a Proapoptotic Gene-- Previous studies have shown that the Bax genes contain p53 response elements in their promoter and that their expression is transcriptionally regulated by functional p53 (3). As a member of the Bcl-2 family, Bax is required to initiate a p53-dependent cell death pathway in neurons (33, 34). Therefore, we examined whether Akt activation inhibits p53-mediated Bax expression. Cells were infected with both AxCre (2 m.o.i.) and AxAkt (10 m.o.i.) or AxLacZ (10 m.o.i.) or with AxKDAkt (10 m.o.i.) alone and allowed to rest for 24 h before treatment with hypoxia, with SNP (50 µM), or with infection with Adp53 (50 m.o.i.) for another 24 h. Expression of active Akt, but not the kinase-defective form of Akt, significantly inhibited up-regulation of Bax mRNA levels following exposure of cells to hypoxia, to SNP or to infection with p53 adenovirus, as assessed by RT-PCR (Fig. 6A). Similar to increasing mRNA levels, Western blot analysis also revealed that expression of active Akt, but not kinase-defective Akt, blocked the p53-mediated increase of Bax protein levels (Fig. 6B).



View larger version (41K):
[in this window]
[in a new window]
 
Fig. 6.   Akt kinase activation inhibits p53-mediated expression of Bax. Cultured hippocampal neurons were infected with AxCANCre (2 m.o.i.) and AxCALNLZ (10 m.o.i.; lanes 1 and 2) or AxCALNLmyrAkt (10 m.o.i.; lane 3), or AxCAAktK179M (10 m.o.i.; lane 4). 24 h after infection, neurons were exposed to hypoxia or SNP (50 µM) or infected with Ad5CMVp53 (50 m.o.i.). Lane 1, control LacZ-expressing cells without treatment with hypoxia, SNP, or Ad5CMVp53. A, RT-PCR for bax mRNA. At 24 h after treatment with hypoxia, SNP (50 µM) or Ad5CMVp53 (50 m.o.i.), total RNA was extracted from neurons and RT-PCR for Bax and beta -actin gene was performed using cDNAs made from total RNA as template. Results were confirmed by three repeated assays. B, Western blot analysis for Bax. At 24 h after treatment with hypoxia, SNP, or Ad5CMVp53, extracts of neurons were subjected to 10% SDS-PAGE and the blots were probed with antibodies to Bax and beta -actin. Results were confirmed by three repeated assays.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the present study, we demonstrate that Akt can significantly inhibit p53-mediated neuronal death by reducing the ability of p53 to transactivate gene transcription. Previous data showed that p53 is up-regulated in neuronal cells in response to diverse insults such as ischemia, and Bax-mediated caspase-3 activation plays an important role in p53-induced apoptosis of neuronal cells (35). In this study, treatment of p53-null neurons with hypoxia or a NO donor turned out to reduce the induction levels of caspase-3-like activity, DNA fragmentation and neuronal death when compared with those of wild-type neurons. Exogenous adenovirus-mediated transduction of p53 expression in p53-deficient neurons up-regulated caspase-3-like activity and induced caspase-dependent DNA fragmentation. These results strongly suggest that p53 expression induced by treatments with hypoxia or a NO donor is responsible for a large portion of caspase-mediated apoptosis in primary hippocampal neurons.

A variety of mammalian cells are dependent on growth factors for their survival. Certain growth factors may also confer protection against apoptosis by stimulating PI 3-kinase and/or a downstream effector, the Akt kinase, in various cell types including neuronal cells (36). The present study showed that IGF-1 blocked p53-mediated caspase-3-like activation and cell death via PI 3-kinase. Adenovirus-mediated expression of active Akt inhibits caspase-3-like proteolytic activity and protects neurons from apoptosis induced by hypoxia, SNP, or p53 adenovirus treatment. These results clearly indicate that activation of Akt is capable of suppressing the caspase-mediated neuronal death that is provoked by p53 expression.

How does Akt activation inhibit p53-mediated neuronal death? The final outcome of p53 activation depends upon many factors including the downstream targets associated with growth control and cell cycle checkpoints (p21, GADD45, MDM2), DNA repair (GADD45, p21, PCNA), and apoptosis (Bax, Bcl-x, Fas, IGF-BP) (37). Sequence-specific transactivation is required for p53-induced apoptosis in specific experimental systems (38). On the other hand, p53-mediated apoptosis does not necessarily require transcriptional activation (39). Here, we show that the p53 protein induced by treatments with hypoxia, with SNP, or with p53 adenovirus infection appears to serve as a site-specific transcription factor that transactivates pro-apoptotic genes such as Bax. In addition, the increase in p53's transcriptional activity was inhibited by expression of active Akt, but not of kinase-defective Akt. This observation was further confirmed by endogenous activation of Akt induced by IGF-1. Furthermore, p53-mediated Bax expression was also inhibited by expression of active Akt. Considering the previous observations that demonstrate a role of Bax in p53-mediated cell death (33, 34), our results suggest that activation of Akt kinase serves to protect neurons from apoptosis, at least in part, by inhibiting the transcriptional activity of p53.

There are several mechanisms that may explain how Akt suppresses transcriptional activity of p53. Several factors appear to contribute to the regulation of p53's transcriptional activity including post-translational protein modification, status of protein conformation, p53 protein levels, and its cellular localization (40). In our experiments, activated Akt had no effect on the protein accumulation and nuclear translocation of p53. In addition, Akt activation has no effect on phosphorylation status of p53. Considering that essentially all activated Akt translocates into nucleus where it functions to phosphorylate proteins (41), these data suggest that Akt phosphorylates coactivators that directly or indirectly modify p53's transcriptional activity, thereby reducing p53-mediated transcriptional activity and apoptosis. Additional experiments will be required to determine the precise mechanism by which activation of Akt kinase inhibits p53's transcriptional activity.

In summary, we propose a novel mechanism in which activation of Akt inhibits p53-mediated neuronal death. More specifically, we report that Akt activation inhibits the transcriptional activity of p53, which we show leads to a reduction of Bax expression and a reduction in neuronal apoptosis. Thus, in addition to interfering with apoptotic events involving Bad and caspase-9, Akt activation appears to be capable of suppressing p53's function at the level of p53-mediated transcription.


    ACKNOWLEDGEMENT

We thank Dr. Saito (University of Tokyo, Tokyo, Japan) for providing AxCANCre, AxCANLZ, and AxCALNLZ; Dr. Kikkawa (Kobe University, Kobe, Japan) for providing pBT-701 containing Akt1 K179M; and Dr. Roth (University of Texas, Houston, TX) for providing Ad5CMVp53.


    FOOTNOTES

* This work was supported by Core Research for Evolutional Science and Technology of Japan Science and Technology.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom all correspondence and reprint requests should be addressed. Tel.: 81-6-6879-3221; Fax: 81-6-6879-3229; E-mail: tama@anat2.med.osaka-u.ac.jp.

Published, JBC Papers in Press, October 27, 2000, DOI 10.1074/jbc.M008552200


    ABBREVIATIONS

The abbreviations used are: IGF-1, insulin-like growth factor-1; Ad, adenovirus; m.o.i., multiplicity of infection; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; PI 3-kinase, phosphatidylinositol 3-kinase; RT, reverse transcriptase; PCR, polymerase chain reaction; DIV, days in vitro; CMV, cytomegalovirus; AMC, 7-amino-4-methylcoumarin; SNP, sodium nitroprusside.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Burns, T. F., and El-Deiry, W. S. (1999) J. Cell. Physiol. 181, 231-239[CrossRef][Medline] [Order article via Infotrieve]
2. Halterman, M. W., and Federoff, H. J. (1999) Exp. Neurol. 159, 65-72[CrossRef][Medline] [Order article via Infotrieve]
3. Miyashita, T., and Reed, J. C. (1995) Cell 80, 293-299[Medline] [Order article via Infotrieve]
4. Wu, G. S., Burns, T. F., McDonald, E. R., III, Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D. D., Zhou, J. Y., Muschel, R., Hamilton, S. R., Spinner, N. B., Markowitz, S., Wu, G., and el-Deiry, W. S. (1997) Nat. Genet. 17, 141-143[Medline] [Order article via Infotrieve]
5. Dore, S., Kar, S., and Quirion, R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4772-4777[Abstract/Free Full Text]
6. Downward, J. (1998) Curr. Opin. Cell Biol. 10, 262-267[CrossRef][Medline] [Order article via Infotrieve]
7. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. (1997) Science 275, 661-665[Abstract/Free Full Text]
8. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. (1995) Cell 81, 727-736[Medline] [Order article via Infotrieve]
9. Kulik, G., and Weber, M. J. (1998) Mol. Cell. Biol. 18, 6711-6718[Abstract/Free Full Text]
10. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-241[Medline] [Order article via Infotrieve]
11. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. (1997) Science 278, 687-689[Abstract/Free Full Text]
12. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. (1998) Science 282, 1318-1321[Abstract/Free Full Text]
13. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., and Donner, D. B. (1999) Nature 401, 82-85[CrossRef][Medline] [Order article via Infotrieve]
14. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Cell 96, 857-868[Medline] [Order article via Infotrieve]
15. Rena, G., Guo, S., Cichy, S. C., Unterman, T. G., and Cohen, P. (1999) J. Biol. Chem. 274, 17179-17183[Abstract/Free Full Text]
16. Tang, E. D., Nunez, G., Barr, F. G., and Guan, K. L. (1999) J. Biol. Chem. 274, 16741-16746[Abstract/Free Full Text]
17. Tsukada, T., Tomooka, Y., Takai, S., Ueda, Y., Nishikawa, S., Yagi, T., Tokunaga, T., Takeda, N., Suda, Y., Abe, S., et al.. (1993) Oncogene 8, 3313-3322[Medline] [Order article via Infotrieve]
18. Tamatani, M., Ogawa, S, Niitsu, Y., and Tohyama, M. (1998) J. Neurochem. 71, 1588-1596[Medline] [Order article via Infotrieve]
19. Tamatani, M., Ogawa, S., Nunez, G., and Tohyama, M. (1998) Cell Death Differ. 5, 911-919[CrossRef][Medline] [Order article via Infotrieve]
20. Ogawa, S., Gerlach, H., Esposito, C., Pasagian-Macaulay, A., Brett, J., and Stern, D. (1990) J. Clin. Invest. 85, 1090-1098[Medline] [Order article via Infotrieve]
21. Matsuzaki, H., Tamatani, M., Mitsuda, N., Namikawa, K., Kiyama, H., Miyake, S., and Tohyama, M. (1999) J. Neurochem. 73, 2037-2046[Medline] [Order article via Infotrieve]
22. Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Gene (Amst.) 108, 193-199[CrossRef][Medline] [Order article via Infotrieve]
23. Zhang, W. W., Fang, X., Mazur, W., French, B. A., Georges, R. N., and Roth, J. A. (1994) Cancer Gene Ther. 1, 5-13[Medline] [Order article via Infotrieve]
24. Tamatani, M., Mitsuda, N., Matsuzaki, H., Okado, H., Miyake, S., Vitek, M. P., Yamaguchi, A., and Tohyama, M. (2000) J. Neurochem. 75, 683-693[CrossRef][Medline] [Order article via Infotrieve]
25. Tamatani, M., Che, Y. H., Matsuzaki, H., Ogawa, S., Okado, H., Miyake, S., Mizuno, T., and Tohyama, M. (1999) J. Biol. Chem. 274, 8531-8538[Abstract/Free Full Text]
26. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract]
27. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) Nat. Genet. 1, 45-49[Medline] [Order article via Infotrieve]
28. Xia, Z., Dudek, H., Miranti, C. K., and Greenberg, M. E. (1996) J. Neurosci. 16, 5425-5436[Abstract/Free Full Text]
29. Ahmad, F., Cong, L. N., Stenson, Holst, L., Wang, L. M., Rahn, Landstrom, T., Pierce, J. H., Quon, M. J., Degerman, E., and Manganiello, V. C. (2000) J. Immunol. 164, 4678-4688[Abstract/Free Full Text]
30. Guan, J., Gunn, A. J., Sirimanne, E. S., Tuffin, J., Gunning, M. I., Clark, R., and Gluckman, P. D. (2000) J. Cereb. Blood Flow Metab. 20, 513-519[Medline] [Order article via Infotrieve]
31. Levine, A. J. (1997) Cell 88, 323-331[Medline] [Order article via Infotrieve]
32. Eves, E. M., Xiong, W., Bellacosa, A., Kennedy, S. G., Tsichlis, P. N., Rosner, M. R., and Hay, N. (1998) Mol. Cell. Biol. 18, 2143-2152[Abstract/Free Full Text]
33. Johnson, M. D., Xiang, H., London, S., Kinoshita, Y., Knudson, M., Mayberg, M., Korsmeyer, S. J., and Morrison, R. S. (1998) J. Neurosci. Res. 54, 721-733[CrossRef][Medline] [Order article via Infotrieve]
34. Xiang, H., Kinoshita, Y., Knudson, C. M., Korsmeyer, S. J., Schwartzkroin, P. A., and Morrison, R. S. (1998) J. Neurosci. 18, 363-373
35. Cregan, S. P., MacLaurin, J. G., Craig, C. G., Robertson, G. S., Nicholson, D. W., Park, D. S., and Slack, R. S. (1999) J. Neurosci. 19, 7860-7869[Abstract/Free Full Text]
36. Crowder, R. J., and Freeman, R. S. (1998) J. Neurosci. 18, 2933-2943[Abstract/Free Full Text]
37. Amundson, S. A., Myers, T. G., and Fornace, A. J., Jr. (1998) Oncogene 17, 3287-3299[CrossRef][Medline] [Order article via Infotrieve]
38. Attardi, L. D., Lowe, S. W., Brugarolas, J., and Jacks, T. (1996) EMBO J. 15, 3693-3701[Medline] [Order article via Infotrieve]
39. Caelles, C., Helmberg, A., and Karin, M. (1994) Nature 370, 220-223[CrossRef][Medline] [Order article via Infotrieve]
40. Jimenez, G. S., Khan, S. H., Stommel, J. M., and Wahl, G. M. (1999) Oncogene 18, 7656-7665[CrossRef][Medline] [Order article via Infotrieve]
41. Coffer, P. J., Jin, J., and Woodgett, J. R. (1998) Biochem. J. 335, 1-13[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.